Form 4: Tandem Diabetes Care Director Christopher J. Twomey Reports Significant Stock Transactions

Tandem Diabetes Care Inc. Director Christopher J. Twomey reported the acquisition of 4,387 shares of common stock through the vesting of restricted stock units and the grant of 8,759 new restricted stock units.

Summary

• Christopher J. Twomey, a Director at Tandem Diabetes Care Inc. (TNDM), reported changes in his beneficial ownership of company securities.
• On May 22, 2025, Mr. Twomey acquired 4,387 shares of common stock at a price of $20.64 per share. This acquisition resulted from the vesting and conversion of previously awarded Restricted Stock Units (RSUs).
• Following this transaction, Mr. Twomey directly beneficially owns 15,675 shares of common stock.
• He also indirectly beneficially owns 5,112 shares through the Chris J. Twomey and Rebecca J. Twomey Family Trust and 7,568 shares through Twomey Family Investments, LLC.
• On May 21, 2025, Mr. Twomey was granted 8,759 new Restricted Stock Units (RSUs) under the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan. These RSUs represent a contingent right to receive common stock and are set to vest on the one-year anniversary of the grant date.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The report indicates a director's continued participation in the company's equity incentive plan, including the vesting of prior awards and the grant of new ones. This suggests ongoing commitment and alignment of interests, which is generally viewed favorably. There are no negative transactions (e.g., large sales) reported.

Positives

• The grant of 8,759 new Restricted Stock Units (RSUs) to Director Christopher J. Twomey indicates continued alignment of management incentives with shareholder interests and confidence in the company's future performance.
• The vesting of 4,387 RSUs and subsequent acquisition of common stock demonstrates the successful execution of the company's long-term incentive plan.

Future Outlook

The new grant of 8,759 Restricted Stock Units (RSUs) to Director Twomey, which will vest on the one-year anniversary of the grant date (May 21, 2026), indicates a future equity award conversion.

Industry Context

This Form 4 filing reports routine insider transactions related to equity compensation for a director of Tandem Diabetes Care Inc., a company in the medical device and diabetes management industry. Such filings are common for publicly traded companies as part of their executive compensation and governance practices, reflecting the ongoing alignment of executive interests with company performance through stock-based incentives.

Comparison to Industry Standards

• The transactions reported, specifically the grant and vesting of Restricted Stock Units (RSUs), are standard practices for executive and director compensation in the medical device and broader technology industries.
• Companies like Medtronic (MDT), Dexcom (DXCM), and Insulet (PODD) also utilize similar long-term incentive plans to align management with shareholder value.
• The specific number of units granted or vested is relative to the individual's compensation package and the company's overall equity compensation strategy, which varies widely across companies based on size, performance, and compensation philosophy.
• Without specific compensation benchmarks for directors at comparable companies, a direct quantitative comparison is not feasible from this document alone.

Corporate Governance

Related Party Transactions

• Indirect beneficial ownership of 5,112 shares is held by the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002.
• Indirect beneficial ownership of 7,568 shares is held by Twomey Family Investments, LLC, where the Reporting Person is a co-manager and shares voting and investment power. The Reporting Person disclaims beneficial ownership except to the extent of his proportionate pecuniary interest.

Stakeholder Impact

• Shareholders: The grant of new RSUs and the vesting of existing ones for a director align management's interests with shareholder value creation, potentially signaling confidence in future performance.
• Employees: The 2023 Long-Term Incentive Plan, under which these awards are made, is a standard mechanism for employee and executive compensation, potentially impacting morale and retention.

Next Steps

• The 8,759 Restricted Stock Units granted on May 21, 2025, are expected to vest on the one-year anniversary of the grant date (May 21, 2026), subject to the terms of the 2023 Plan.

Key Dates

Recommendation

Keywords

Tandem Diabetes Care, TNDM, SEC Form 4, Insider Trading, Stock Ownership, Restricted Stock Units, RSU, Director, Equity Compensation, Beneficial Ownership